Suppr超能文献

癌症幸存者中第二原发甲状腺癌的风险。

Risk of second primary thyroid cancer in cancer survivors.

机构信息

Department of Breast Surgery, Sichuan Provincial Maternity and Child Health Care Hospital, No. 290 West Second Street, Shayan Road, Chengdu, 610031, Sichuan, China.

Department of Thyroid and Breast Surgery, The General Hospital of Western Theater Command, Chengdu, 610083, Sichuan, China.

出版信息

Sci Rep. 2024 May 30;14(1):12478. doi: 10.1038/s41598-024-63155-z.

Abstract

A risk factor for thyroid cancer (TC) may be a history of former cancer and cancer therapy. The precise risk of a second primary thyroid carcinoma has not yet been revealed. In this study, we evaluated standardized incidence ratios (SIRs) of second primary thyroid cancer (SPTC) with consideration of different conditions and further analyzed the clinicopathological characteristics and survival of these patients. The cohort was selected from the US Surveillance, Epidemiology, and End Results (SEER) Program between 1975 and 2019. The standardized incidence ratios, morbidity risk, clinicopathological features, and survival of second primary thyroid carcinoma were analyzed. Propensity score matching (PSM) was used to balance covariates. Kaplan-Meier method was performed to assess the survival outcomes. Overall, 7066 patients with SPTC and 83,113 patients with primary TC were identified. The SIR of TC in tumor patients was 1.51/10,000, statistically higher than the natural population (0.94/10,000, P < 0.05). The most significant tumors contributing to the increased SIRs of SPTC were acute lymphocytic leukemia (3.49/10,000), Hodgkin's lymphoma-nodal (3.29/10,000), salivary gland cancer (3.23/10,000), and kidney and renal pelvis cancer (3.05/10,000). The incidence of TC increased significantly in tumor patients who received radiotherapy/chemotherapy before age 35. The age at diagnosis of the SPTC was much older than the primary TC (64.01 vs. 49.55 years, p < 0.001). The SPTC had a higher percentage of histological grades 3/4 (23.14% vs. 15.19%, p < 0.001). Survival analyses demonstrated a worse prognosis for the SPTC group compared to the primary TC group. But after PSM, the survival outcomes of the two groups tended to be equivalent (P = 0.584). The SIRs of TC are higher in tumor patients. The most significant factors contributing to the increased risk of SPTC were some specific former tumors and acceptance of radiotherapy/ chemotherapy before age 35. There was no significant difference in survival between SPTC and primary TC.

摘要

甲状腺癌 (TC) 的风险因素可能是既往癌症和癌症治疗史。第二原发甲状腺癌的确切风险尚未揭示。在这项研究中,我们评估了考虑不同条件后的第二原发甲状腺癌 (SPTC) 的标准化发病比 (SIR),并进一步分析了这些患者的临床病理特征和生存情况。该队列是从 1975 年至 2019 年美国监测、流行病学和最终结果 (SEER) 计划中选择的。分析了第二原发甲状腺癌的标准化发病比、发病率风险、临床病理特征和生存情况。采用倾向评分匹配 (PSM) 平衡协变量。采用 Kaplan-Meier 法评估生存结局。总体而言,共确定了 7066 例 SPTC 患者和 83113 例原发性 TC 患者。肿瘤患者 TC 的 SIR 为 1.51/10000,明显高于自然人群 (0.94/10000,P<0.05)。导致 SPTC 的 SIR 增加的最显著肿瘤是急性淋巴细胞白血病 (3.49/10000)、霍奇金淋巴瘤-结外 (3.29/10000)、唾液腺癌 (3.23/10000) 和肾和肾盂癌 (3.05/10000)。35 岁前接受放化疗的肿瘤患者 TC 发病率显著增加。SPTC 的诊断年龄明显大于原发性 TC(64.01 岁比 49.55 岁,p<0.001)。SPTC 组织学分级 3/4 的比例较高 (23.14%比 15.19%,p<0.001)。生存分析显示 SPTC 组的预后明显差于原发性 TC 组。但经 PSM 后,两组的生存结果趋于一致(P=0.584)。TC 的 SIR 在肿瘤患者中较高。导致 SPTC 风险增加的最重要因素是某些特定的既往肿瘤和 35 岁前接受放疗/化疗。SPTC 和原发性 TC 的生存无显著差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f54b/11139851/8da05f6a1118/41598_2024_63155_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验